Gene Expression Profiling for Melanoma and cSCC

CE / CME

Precision Skin Cancer Diagnosis: Gene Expression Profiling for Melanoma and cSCC

Nurse Practitioners: 1.00 AANP contact hour

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Released: September 30, 2022

Expiration: September 30, 2023

Sylvana Brickley
Sylvana Brickley, DNP, FNP-BC, DCNP
Aaron S. Farberg
Aaron S. Farberg, MD, FAAD
Cynthia Griffith
Cynthia Griffith, MPAS, PA-C
Sherrif Ibrahim
Sherrif Ibrahim, MD, PhD

Pretest

Progress
1 2
Course Completed
1.

How confident are you in your ability to diagnose and risk stratify patients with melanoma or cutaneous squamous cell carcinoma?

2.

A 58-year-old male patient is concerned about a mole he has noticed on his arm. Based on initial examination, you suspect melanoma and request a biopsy to confirm. The biopsy suggests melanoma, but the results aren’t conclusive, and you are considering gene expression profiling to confirm. When discussing GEP testing with your patient, which of the following pieces of information would you provide?

3.

Which of the following was observed in a clinical trial of the 23-GEP (MyPath Melanoma) diagnostic test for melanoma?

4.

Which of the following is true regarding the 40-GEP test for cSCC risk stratification?

5.

Patricia is a 46-year-old woman with a mole on her right lower leg that has been identified as melanoma. Wide local excision reveals Breslow thickness of 1.2 mm and ulceration. She is SLNB negative but is very anxious about her disease. How would you proceed with this patient?